Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

BL-M05D1

Phase 3Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

BL-M05D1 is one of 87 small molecule programs targeting Gastric Cancer. It is currently in Phase 3.

3

Indications

3

Total Trials

3

Active Trials

86

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastric CancerRecruiting

Locally Advanced or Metastatic Solid TumorsRecruiting

Gastric AdenocarcinomaActive, not recruiting

Gastric CancerPhase 3

Recruiting

Locally Advanced or Metastatic Solid TumorsPhase 1

Recruiting

Gastric AdenocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Taxol

Opdivo

Bristol-Myers Squibb

Camptosar

Keytruda

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Taxotere

Abraxane

Bristol-Myers Squibb

Avastin

Beyfortus

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Active, not recruiting

Gastric Adenocarcinoma

NCT07021066

Q4 2029

Phase 3Recruiting

Gastric Cancer

NCT07518147

Clinical

Trials by Indication[1]

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT06349811·30 enrolled

Gastric Adenocarcinoma1 trial

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Advanced or Metastatic Solid Tumors

Active, not recruiting·SSystImmune Inc.·Phase 1·NCT07021066·160 enrolled

Gastric Cancer1 trial

A Randomized Controlled Phase III Clinical Study Comparing BL-M05D1 for Injection With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN) 18.2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-line Treatment

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 3·NCT07518147·438 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BL-M05D1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL-M05D1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL-M05D1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

Related News